source
- Boehringer Ingelheim to invest up to $1B in AI-driven solid tumor partnership with EnvisagenicsBoehringer Ingelheim announced a partnership with Envisagenics to develop precision oncology therapies that use artificial intelligence to identify cancer-specific RNA splicing alterations. The co…
- Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorderWith a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could supp…